ADMA Biologics, Inc. (ADMA)
NASDAQ: ADMA · Real-Time Price · USD
12.79
+0.06 (0.47%)
At close: Nov 9, 2026, 4:00 PM EST
12.64
-0.15 (-1.15%)
After-hours: Nov 9, 2026, 7:35 PM EST
ADMA Biologics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 519.15 | 510.17 | 426.45 | 258.22 | 154.08 | 80.94 | |
Revenue Growth | 6.26% | 19.63% | 65.16% | 67.58% | 90.36% | 91.72% |
Cost of Revenue | 163.39 | 217.41 | 206.9 | 169.27 | 118.82 | 79.77 |
Gross Profit | 355.76 | 292.77 | 219.55 | 88.94 | 35.27 | 1.17 |
Selling, General & Admin | 107.82 | 96.42 | 78.37 | 62.59 | 70.3 | 55.19 |
Research & Development | 14.48 | 4.76 | 1.81 | 3.3 | 3.61 | 2.85 |
Amortization of Goodwill & Intangibles | 0.22 | 0.14 | 0.39 | 0.72 | 0.72 | 0.72 |
Operating Expenses | 122.51 | 101.32 | 80.57 | 66.61 | 74.63 | 58.75 |
Operating Income | 233.25 | 191.44 | 138.98 | 22.33 | -39.37 | -57.57 |
Interest Expense | -10.58 | -7.11 | -13.93 | -25.03 | -19.28 | -13.06 |
Interest & Investment Income | 4.12 | 1.87 | 2.1 | 1.62 | 0.05 | 0.04 |
Other Non Operating Income (Expenses) | -0.2 | -0.21 | -0.19 | -0.29 | -0.64 | -0.25 |
EBT Excluding Unusual Items | 226.58 | 185.99 | 126.96 | -1.37 | -59.23 | -70.85 |
Gain (Loss) on Sale of Assets | 7.98 | - | - | - | - | - |
Other Unusual Items | - | -3.34 | -1.24 | -26.87 | -6.67 | -0.8 |
Pretax Income | 234.56 | 182.66 | 125.71 | -28.24 | -65.9 | -71.65 |
Income Tax Expense | 52.15 | 35.73 | -71.96 | - | - | - |
Net Income | 182.41 | 146.93 | 197.67 | -28.24 | -65.9 | -71.65 |
Net Income to Common | 182.41 | 146.93 | 197.67 | -28.24 | -65.9 | -71.65 |
Net Income Growth | -12.91% | -25.67% | - | - | - | - |
Shares Outstanding (Basic) | 231 | 238 | 233 | 224 | 198 | 140 |
Shares Outstanding (Diluted) | 235 | 245 | 233 | 224 | 198 | 140 |
Shares Change | -1.28% | 5.07% | 4.07% | 13.19% | 41.77% | 62.03% |
EPS (Basic) | 0.79 | 0.62 | 0.85 | -0.13 | -0.33 | -0.51 |
EPS (Diluted) | 0.77 | 0.60 | 0.81 | -0.13 | -0.33 | -0.51 |
EPS Growth | -9.38% | -25.93% | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | 132.91 | 27.82 | 110.45 | 4.03 | -73.42 | -125.88 |
Free Cash Flow Per Share | 0.57 | 0.11 | 0.47 | 0.02 | -0.37 | -0.90 |
Gross Margin | 68.53% | 57.38% | 51.48% | 34.45% | 22.89% | 1.45% |
Operating Margin | 44.93% | 37.52% | 32.59% | 8.65% | -25.55% | -71.13% |
Profit Margin | 35.14% | 28.80% | 46.35% | -10.94% | -42.77% | -88.52% |
Free Cash Flow Margin | 25.60% | 5.45% | 25.90% | 1.56% | -47.65% | -155.52% |
EBITDA | 240.7 | 199.54 | 147.03 | 30.66 | -32.25 | -52.08 |
EBITDA Margin | 46.36% | 39.11% | 34.48% | 11.88% | -20.93% | -64.34% |
D&A For EBITDA | 7.46 | 8.1 | 8.05 | 8.33 | 7.11 | 5.5 |
EBIT | 233.25 | 191.44 | 138.98 | 22.33 | -39.37 | -57.57 |
EBIT Margin | 44.93% | 37.52% | 32.59% | 8.65% | -25.55% | -71.13% |
Effective Tax Rate | 22.23% | 19.56% | - | - | - | - |